LOC100506691は,肺がん細胞の成長と運動を促進する腫瘍性長いノンコーディングRNAです.
PubMedで要約を見る
まとめ
この要約は機械生成です。LOC100506691は,新しい長いノンコーディングRNAで,肺がんの成長と転移を促進します. 肺癌の増殖を抑制し,アポトーシスを誘発し,肺癌の治療対象となる可能性があります.
科学分野
- 腫瘍学
- 分子生物学
- 遺伝学
背景
- 肺がんは世界中で がんによる死亡の主な原因です
- 長い非コーディングRNA (lncRNAs) は癌細胞の増殖,アポトーシス,転移を制御する.
- 肺がんにおけるLOC100506691の役割は,現在不明である.
研究 の 目的
- 肺がんにおけるLOC100506691の発現と臨床的意義を調査する.
- 肺がんの進行におけるLOC100506691の生物学的な機能を解明する.
- LOC100506691によって制御される 基礎的な分子機構を探求する.
主な方法
- 公開データベースを用いたLOC100506691の表現と臨床的相関の分析
- 肺がん細胞系におけるLOC100506691の siRNA媒介によるノックダウン.
- 細胞増殖,コロニー形成,運動性,アポトーシス,細胞サイクル進行の評価
- 影響を受けたシグナル伝達経路を特定するためのウェスタン・ブロッティングと経路濃縮分析.
主要な成果
- LOC100506691の発現は,正常な組織と比較して肺がん組織で著しく上位調節されます.
- 高値のLOC100506691は,患者の生存率の低下と相関しています.
- LOC100506691 ノックダウンは増殖,コロニー形成,転移を抑制した.
- PI3K/ AKT経路の調節を含むノックダウン誘発細胞サイクル停止とアポトーシス.
結論
- LOC100506691は,肺がんの成長と転移を促進する新しい発がん性 lncRNAです.
- LOC100506691は,肺がん治療の潜在的な治療目標です.
- これらの発見は,肺がん発生のメカニズムと治療戦略の洞察を提供します.
関連する概念動画
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

